EpiCor reduces flu symptoms in children
Efficacy of a yeast postbiotic on cold/flu symptoms in healthy children: A randomized-controlled trial.
We examined the impact of EpiCor, a yeast-derived postbiotic, on flu symptoms in healthy children. In a study involving 256 kids aged 4-12, participants took either EpiCor or a placebo for 84 days during the flu season.
The results were promising! Kids receiving EpiCor experienced significantly reduced severity of cold/flu symptoms and relied less on cold medications compared to those on the placebo. Overall, EpiCor proved to be a safe option for bolstering immune function in young children.
Read More
Probiotics reduce flu symptoms
Effectiveness of Multistrain Probiotic Formulation on Common Infectious Disease Symptoms and Gut Microbiota Modulation in Flu-Vaccinated Healthy Elderly Subjects.
We conducted a study to see if probiotics could make a difference for flu-vaccinated elderly individuals. Fifty participants in a double-blind, placebo-controlled trial took a multistrain probiotic for 28 days.
After this period, we noticed a decrease in both symptoms and incidence of common infections in those who received the probiotics. Additionally, we found promising changes in immune system markers and gut health. This indicates that probiotics might improve protection against infections by boosting immunity and positively influencing gut microbiota.
Read More
Probiotics reduce flu-related costs
Probiotics Reduce Health Care Cost and Societal Impact of Flu-Like Respiratory Tract Infections in the USA: An Economic Modeling Study.
We explored how probiotics can reduce the health care costs and societal impacts of flu-like respiratory infections. By using a state-transition microsimulation model, we investigated various scenarios to estimate the economic benefits of probiotics in 2017-2018.
Our findings revealed potential savings of $4.6 million to $1.4 billion, depending on the source of data analyzed. Overall, fewer RTI episodes led to less medical intervention and fewer missed workdays.
While the results suggest probiotics could alleviate some burden on health systems, this study focuses mainly on economic modeling rather than direct clinical effectiveness.
Read More
Probiotics show promise against influenza
Immune responses of mice inoculated with recombinant Lactobacillus plantarum NC8 expressing the fusion gene HA2 and 3M2e of the influenza virus and protection against different subtypes of influenza virus.
We investigated the potential of two recombinant probiotics, Lactobacillus plantarum NC8-409-1 and NC8-409-2, in preventing influenza in mice. These vaccines successfully triggered immune responses, notably increasing specific antibodies in both the intestine and serum.
Notably, NC8-409-2 demonstrated substantial protection against H9N2—up to 80%—while NC8-409-1 showed about 60% protection against H1N1. Although these results hint at exciting possibilities for developing oral vaccines against avian flu, the overall effectiveness against human flu is uncertain.
Read More
Lactobacillus shows promise against flu
Heat-killed Lactobacillus gasseri TMC0356 protects mice against influenza virus infection by stimulating gut and respiratory immune responses.
We explored the effects of heat-killed Lactobacillus gasseri TMC0356 on mice infected with the flu virus. After 19 days of treatment, we observed improved clinical symptoms, reduced viral loads, and enhanced immune responses in the treated mice compared to controls. This suggests that Lactobacillus could bolster both gut and respiratory immunity against influenza. However, these exciting results are limited to animal studies, and further research in humans is needed to fully understand its benefits.
Read More